Acute Myeloid Leukemia (AML)

Dr. Patel is an Assistant Professor at the University of Nebraska Medical Center. His reasearch interests include: Hematopoietic stem cell transplantation; alternative donors transplant including umbilical cord blood, transplantation of malignant and non-malignant disease.

Dr. Ron Paquette is a member of the Blood and Marrow Transplant Program at Cedars-Sinai. He is a physician and researcher who treats patients with hematologic disorders including aplastic anemia, myelodysplastic syndrome, leukemias and lymphomas. He attended medical school at The Ohio State University, completed his Internal Medicine residency and Hematology-Oncology fellowship at the University of California, Los Angeles. He was previously a faculty member at UCLA before joining Cedars-Sinai Medical Center.

Dr. Olson's clinical efforts focus on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure. Through his combined clinical activities in the Bone Marrow Failure Center within the Division of Hematology and the Blood and Marrow Transplant Section within the Division of Oncology, his goal is to facilitate outstanding care for patients with inherited bone marrow failure and acquired aplastic anemia during their transition from diagnostic evaluation to treatment through HSCT. In coordination with

Dr. Pollyea received his MD degree from the University of Chicago Pritzker School of Medicine. He stayed at the University of Chicago Hospital for his residency in Internal Medicine and served as Chief Medical Resident at Cook County Hospital. He then completed his fellowship training in Hematology and Oncology at Stanford University, where he also completed a Masters degree in Epidemiology with an emphasis on biostatistics and clinical trial design. In 2011 he came to the University of Colorado where he is currently the Clinical Director of Leukemia Services. Dr. Pollyea has served as the

As a blood cancer specialist and also a palliative care physician, Dr. LeBlanc bring a different focus to cancer care. He is working hard to improve the treatment experience for patients who are living with blood cancers. By understanding your experience better, Dr. LeBlanc believes we can develop new ways to improve your quality of life, and provide additional support throughout your treatment and beyond.

Dr. Meyers was born and raised in rural Northern California and traveled around the country during her medical training. She developed an interest in hematology and oncology during medical school, and pursued a fellowship in that field after her internal medicine residency. While at the University of Utah, she performed laboratory research on bone marrow failure syndromes, with a focus on paroxysmal nocturnal hemoglobinuria. Her research continues at OHSU, and she currently has government and private foundation support to study the genetic changes that lead to bone marrow dysfunction and

Ruben A. Mesa, MD, FACP, is the president and executive director of Atrium Health Levine Cancer and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He also serves as vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine. In his roles, Dr. Mesa oversees all efforts related to cancer practice, research and education across the Atrium Health system. Dr. Mesa is an international expert in hematologic cancers. He has dedicated his life's work to research and drug development for myeloproliferative neoplasms (MPNs), a group of chronic

Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based